Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
June, 2026
June 2026
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
Ifeanyichukwu Ifechidere: Coagulation Disorder or DOAC Interference?
Ifeanyichukwu Ifechidere/LinkedIn
Jun 3, 2026, 14:32

Ifeanyichukwu Ifechidere: Coagulation Disorder or DOAC Interference?

Ifeanyichukwu Ifechidere, Specialist Biomedical Scientist at Sheffield Teaching Hospitals NHS Foundation Trust, shared a post on LinkedIn:

“Your patient may Not have protein C deficiency.

Your factor VIII result may Not be low.

And your lupus anticoagulant result may be completely fake.

The culprit?

DOACs.

This is one of the most dangerous misconceptions in coagulation testing:

Many people think DOACs only affect PT/APTT.

They don’t.

DOACs can interfere with almost every corner of haemostasis testing if you don’t recognise their presence first.

And this is where laboratory interpretation becomes critical.

I’ve seen cases where:

  • Patients were wrongly labelled thrombophilic
  • Factor assays appeared falsely reduced
  • Lupus anticoagulant screens became falsely positive
  • Natural anticoagulant results looked abnormal when they weren’t

All because one question was missed:

‘Is this patient on a DOAC?’

Here’s what many people don’t fully appreciate

DOACs interfere differently depending on:

  1. The specific drug
  2. The assay principle
  3. The reagent used
  4. Whether the method is clot-based or chromogenic

Which means the effect is Not uniform.

For example:

Factor Xa inhibitors (apixaban, rivaroxaban, edoxaban) can:

Falsely lower clot-based factor assays

Interfere with antithrombin assays

Distort protein C and protein S testing

Prolong dRVVT and mimic lupus anticoagulants

Dabigatran can:

Markedly prolong thrombin-based assays

Affect clot-based factor levels

Interfere with inhibitor studies

Cause misleading thrombophilia profiles

And this is the scary part:

Sometimes the laboratory result looks perfectly believable.

That’s what makes DOAC interference so dangerous.

Because if you don’t actively think about it…

You may interpret drug effect as disease.

This is why pre-analytical awareness matters just as much as analytical skill.

As biomedical scientists, we must constantly ask:

  • What assay principle is being used?
  • Is this method DOAC-sensitive?
  • Could this ‘abnormality’ be interference instead of pathology?

Because in coagulation, understanding the limitations of the assay is just as important as understanding the disease itself.

And sometimes…

The most important coagulation diagnosis is recognising when the result should Not be trusted.

Join us for our bi-weekly newsletter using the link in the comment section.”

Ifeanyichukwu Ifechidere: Coagulation Disorder or DOAC Interference?

Find more posts featuring Ifeanyichukwu Ifechidere on Hemostasis Today.

Anticoagulation dabigatran Health Hematology Hemostasis News Hemostasis Today Ifeanyichukwu Ifechidere Medicine thrombosis
NewsFeed